Published in World J Urol on January 01, 1996
Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol (2002) 1.83
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis (2013) 1.17
A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet (2001) 1.16
Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol (2011) 1.12
Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer (2001) 1.07
Molecular profiling of clinical tissue specimens: feasibility and applications. Am J Pathol (2000) 1.00
Molecular profiling of clinical tissues specimens: feasibility and applications. J Mol Diagn (2000) 0.98
STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol (2013) 0.84
Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer. Int J Clin Exp Pathol (2015) 0.80
Novel DNA amplification on chromosomes 2p25.3 and 7q11.23 in cholangiocarcinoma identified by arbitrarily primed polymerase chain reaction. J Cancer Res Clin Oncol (2005) 0.79
PROTEOME-3D: an interactive bioinformatics tool for large-scale data exploration and knowledge discovery. Mol Cell Proteomics (2003) 0.78
Myosins as fundamental components during tumorigenesis: diverse and indispensable. Oncotarget (2016) 0.78
XPC intron11 C/A polymorphism as a risk factor for prostate cancer. Environ Health Prev Med (2016) 0.77
Analysis of an independent tumor suppressor locus telomeric to Tp53 suggested Inpp5k and Myo1c as novel tumor suppressor gene candidates in this region. BMC Genet (2015) 0.77
Meta-Analysis of the Relationship between XRCC1-Arg399Gln and Arg280His Polymorphisms and the Risk of Prostate Cancer. Sci Rep (2015) 0.77
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34
Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci U S A (1990) 2.22
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res (1996) 2.04
Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res (1993) 1.96
Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res (2001) 1.67
Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate (1986) 1.65
GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol (2001) 1.60
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol (1998) 1.60
CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev (1998) 1.59
Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene (2011) 1.50
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res (1998) 1.47
Detection and analysis of beta-catenin mutations in prostate cancer. Prostate (2000) 1.43
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer (1997) 1.42
Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet (2001) 1.40
Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer (2003) 1.38
Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet (2001) 1.32
Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics (1996) 1.29
Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res (1995) 1.28
Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A (1992) 1.28
Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res (1997) 1.27
Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics (1996) 1.27
CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev (1997) 1.26
ras gene mutations in human prostate cancer. Cancer Res (1990) 1.24
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res (2001) 1.22
Cotranslational assembly of myosin heavy chain in developing cultured skeletal muscle. Proc Natl Acad Sci U S A (1987) 1.21
Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res (1998) 1.21
Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer (1997) 1.17
Titin, a huge, elastic sarcomeric protein with a probable role in morphogenesis. Bioessays (1991) 1.15
Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res (1995) 1.13
GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas. Int J Oncol (2000) 1.12
Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res (1999) 1.11
The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol (1997) 1.05
Tumor suppressor gene allelic loss in human renal cancers. J Urol (1993) 1.04
An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res (1996) 1.03
No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate (1999) 1.01
A novel human cell culture model for the study of familial prostate cancer. Cancer Res (2001) 1.01
Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res (1992) 1.01
Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer (2003) 0.99
Cadherin-6, a cell adhesion molecule specifically expressed in the proximal renal tubule and renal cell carcinoma. Cancer Res (1997) 0.99
Hereditary prostate cancer in African American families: linkage analysis using markers that map to five candidate susceptibility loci. Br J Cancer (2004) 0.94
Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Genes Chromosomes Cancer (1995) 0.93
Linkage of prostate cancer susceptibility loci to chromosome 1. Hum Genet (2001) 0.93
Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate (2001) 0.91
Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol (2000) 0.90
Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate (1994) 0.90
Molecular advances in prostate cancer. Curr Opin Oncol (1997) 0.90
P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. Clin Cancer Res (1997) 0.89
Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate (1994) 0.89
Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res (1998) 0.88
Hypermethylation of chromosome 17P locus D17S5 in human prostate tissue. J Urol (1996) 0.88
Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). J Intern Med (2012) 0.87
Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun (1994) 0.86
Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Hum Genet (2001) 0.86
Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders. J Vet Intern Med (1995) 0.86
Immunogold probes for electron microscopy: evaluation of staining by fluorescence microscopy. J Histochem Cytochem (1985) 0.86
Time lapse videomicroscopic identification of Dunning R-3327 adenocarcinoma and normal rat prostate cells. J Urol (1987) 0.86
No association between the I105V polymorphism of the glutathione S-transferase P1 gene (GSTP1) and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev (2000) 0.84
The predominant protein of canine seminal plasma is an enzyme. J Biol Chem (1984) 0.84
Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate (1995) 0.84
Vitamin D receptor polymorphisms and lethal prostate cancer. J Urol (1998) 0.84
Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer (1999) 0.83
The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol (1991) 0.82
Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration. Br J Cancer (2011) 0.82
Models for development of nonreceptor methods for distinguishing androgen-sensitive and -insensitive prostatic tumors. Cancer Res (1979) 0.81
The E-cadherin cell-cell adhesion pathway in urologic malignancies. World J Urol (1995) 0.81
A glimpse into the future. Epidemiol Rev (2001) 0.81
Molecular biology of bladder cancer. Hematol Oncol Clin North Am (1992) 0.80
DNA methylation, molecular genetic, and linkage studies in prostate cancer. Prostate Suppl (1996) 0.80
Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer (2001) 0.80
Tumour-suppressor genes in prostatic oncogenesis: a positional approach. Br J Urol (1997) 0.79
Isolation and characterization of the major androgen-dependent glycoprotein of canine prostatic fluid. J Biol Chem (1983) 0.79
Molecular and cellular markers for metastatic prostate cancer. Cancer Metastasis Rev (1993) 0.78
The relationship of cellular structure and function: the matrix system. Prog Clin Biol Res (1981) 0.78
Multiple antibodies to titin immunoreact with AHNAK and localize to the mitotic spindle machinery. Cell Motil Cytoskeleton (2001) 0.78
Assignment of the human alpha-catenin gene (CTNNA1) to chromosome 5q21-q22. Genomics (1994) 0.77
G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology (2000) 0.77
Differential effects of estrogen treatment on canine seminal plasma components. Invest Urol (1980) 0.77
Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. Prostate (1992) 0.76
Comparative aspects of multistep prostatic carcinogenesis in humans and rodents. Prog Clin Biol Res (1992) 0.76
Cerebral injury: are manipulations of carbon dioxide beneficial? J Neurosurg Anesthesiol (1993) 0.76
Molecular genetics of prostate cancer: clinical applications. J Natl Med Assoc (1998) 0.75
Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. Prostate (1990) 0.75
TaqI polymorphism of the human MXI1 gene. Hum Mol Genet (1994) 0.75
Structural and functional components in normal and hyperplastic canine prostates. Prog Clin Biol Res (1984) 0.75
E1A transformed normal human prostate epithelial cells contain a 16q deletion. Cancer Genet Cytogenet (1998) 0.75